Abstract
SUMMARY For the treatment of Type 2 diabetes, incretin-based therapies have been an established treatment since their introduction in 2006. GLP-1 receptor agonists as an injectable therapy and DPP-4 inhibitors as oral antidiabetic agents have a strictly glucose-dependent action on insulin and glucagon secretion, resulting in a negligible intrinsic hypoglycemia risk. The GLP-1 receptor agonists only act by stimulating the GLP-1 receptor directly at receptor ligand concentrations in the pharmacological concentration range. They decelerate gastric emptying dependent on their duration of action and also act directly by stimulating satiety signals in the CNS. These effects lead to a loss of body weight. DPP-4 inhibitors primarily elevate endogenous active GLP-1 plasma concentrations by two- to three-fold. They are body weight neutral since only higher concentrations of GLP-1 than those elicited by DPP-4 inhibitors have direct effects on the CNS or on the retardation of gastrointestinal motility. Novel studies ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
